Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.
Poh ME, How SH, Ho GF, Pang YK, Hasbullah HH, Tho LM, Muhamad Nor I, Lim BC, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Soon SY, Tan JYK, Zainal Abidin MA. Poh ME, et al. Among authors: pang yk. Cancer Manag Res. 2023 Jan 13;15:31-41. doi: 10.2147/CMAR.S393729. eCollection 2023. Cancer Manag Res. 2023. PMID: 36660237 Free PMC article.
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
Rajadurai P, Cheah PL, How SH, Liam CK, Annuar MAA, Omar N, Othman N, Marzuki NM, Pang YK, Bustamam RSA, Tho LM. Rajadurai P, et al. Among authors: pang yk. Lung Cancer. 2019 Oct;136:65-73. doi: 10.1016/j.lungcan.2019.08.005. Epub 2019 Aug 5. Lung Cancer. 2019. PMID: 31446227 Free article. Review.
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
Park K, Jӓnne PA, Kim DW, Han JY, Wu MF, Lee JS, Kang JH, Lee DH, Cho BC, Yu CJ, Pang YK, Felip E, Kim H, Baek E, Noh YS. Park K, et al. Among authors: pang yk. Cancer. 2021 May 1;127(9):1407-1416. doi: 10.1002/cncr.33385. Epub 2021 Jan 12. Cancer. 2021. PMID: 33434335 Free PMC article. Clinical Trial.
Influenza in Malaysian adult patients hospitalized with community-acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease or asthma: a multicenter, active surveillance study.
Pang YK, Ismail AI, Chan YF, Cheong A, Chong YM, Doshi P, Lau JZH, Khor J, Wang LPL, Leong CL, Musa AN, Ng KS, Poh ME, Sam IC, Tan JL, Zim MAM, Taurel AF. Pang YK, et al. BMC Infect Dis. 2021 Jul 5;21(1):644. doi: 10.1186/s12879-021-06360-9. BMC Infect Dis. 2021. PMID: 34225647 Free PMC article.
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country.
How SH, Tho LM, Liam CK, Hasbullah HH, Ho GF, Muhammad Nor I, Poh ME, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Pang YK, Soon SY. How SH, et al. Among authors: pang yk. Thorac Cancer. 2022 Jun;13(11):1676-1683. doi: 10.1111/1759-7714.14442. Epub 2022 May 3. Thorac Cancer. 2022. PMID: 35502623 Free PMC article.
Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia.
How SH, Liam CK, Zainal Abidin MA, Hasbullah HH, Tho LM, Ho GF, Muhamad Nor I, Pang YK, Ho KF, Thiagarajan M, Ariffin R, Samsudin A, Omar A, Tan SN, Ong CK, Soon SY, Poh ME. How SH, et al. Among authors: pang yk. Cancer Manag Res. 2022 Jun 16;14:1995-2005. doi: 10.2147/CMAR.S364713. eCollection 2022. Cancer Manag Res. 2022. PMID: 35733510 Free PMC article.
Pathological complete response in an advance stage IIIB non-small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literature.
Soo CI, Ong DB, Chin KK, Sia LC, Munusamy V, Ibrahim NH, Loh TC, Tan JL, Poh ME, Wong CK, Pang YK, Liam CK. Soo CI, et al. Among authors: pang yk. Respirol Case Rep. 2023 Jun 21;11(7):e01181. doi: 10.1002/rcr2.1181. eCollection 2023 Jul. Respirol Case Rep. 2023. PMID: 37350988 Free PMC article.
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Cho BC, et al. Among authors: pang yk. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379502 Clinical Trial.
97 results